A client has been receiving treatment with antineoplastic drugs that depress the bone marrow.
Which preadministration assessment would be most important for the nurse to complete with respect to this effect?

Choice A rationale:

Alkylating agents. Alkylating agents are not cell cycle-specific. These agents work by directly binding to DNA and interfering with the cell's ability to replicate and divide. Their action is not limited to a specific phase of the cell cycle, making them non-cell cycle-specific agents. Alkylating agents are often used in cancer chemotherapy to prevent cell division and growth.

Choice C rationale:

Antineoplastic antibiotics. Antineoplastic antibiotics are not cell cycle-specific either. These drugs, such as doxorubicin and bleomycin, work by disrupting DNA and RNA synthesis and are used to treat various types of cancer. However, they do not specifically target cells in a particular phase of the cell cycle.

Choice D rationale:

Retinoids. Retinoids are not cell cycle-specific antineoplastic agents. Retinoids are compounds related to vitamin A and are used for various medical purposes, including some cancer treatments. However, their mechanism of action is not tied to a specific phase of the cell cycle, making them non-cell cycle-specific.

Choice B rationale:

Plant alkaloids. Plant alkaloids, such as vinca alkaloids (vincristine and vinblastine) and taxanes (paclitaxel), are considered cell cycle-specific antineoplastic drugs. These agents interfere with microtubule function, which is critical during mitosis (cell division). By disrupting microtubules, they specifically target rapidly dividing cancer cells during the M phase of the cell cycle. This selectivity for actively dividing cells makes plant alkaloids cell cycle-specific antineoplastic drugs.

Choice A rationale:

Isoniazid Isoniazid is one of the first-line drugs used in the initial treatment phase of tuberculosis (TB). It is a key component of the standard regimen for TB treatment. Isoniazid is highly effective against Mycobacterium tuberculosis, the bacterium responsible for TB, and it plays a critical role in the initial phase of treatment to rapidly reduce the bacterial load.

Choice B rationale:

Ciprofloxacin Ciprofloxacin is not a first-line drug for the treatment of tuberculosis. While it has antibacterial properties, it is not considered one of the primary agents for TB treatment. It is more commonly used to treat other types of bacterial infections, such as urinary tract infections.

Choice C rationale:

Gentamycin Gentamycin is not typically used as a first-line treatment for TB. It is reserved for specific situations, such as drug-resistant TB cases, and is not part of the standard initial treatment regimen for TB.

Choice D rationale:

Clindamycin Clindamycin is not a first-line drug for the treatment of tuberculosis. It is primarily used to treat anaerobic bacterial infections and is not a standard part of TB treatment protocols.